4.7 Article

Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients

期刊

BLOOD
卷 118, 期 20, 页码 5416-5419

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-07-366526

关键词

-

资金

  1. Merck Sharp Dohme
  2. Gilead Sciences
  3. Pfizer
  4. Associazione Italiana per la Ricerca sul Cancro, Milan, Italy
  5. European Commission [LSHC-CT-2005-018704]
  6. Associazione Italiana Lotta alle Leucemie, Linfoma e Mieloma-Sezione
  7. Programma di ricerca Regione-Universita
  8. Regione Emilia Romagna
  9. Societa Italiana di Ematologia Sperimentale

向作者/读者索取更多资源

Mucorales-specific T cells were investigated in 28 hematologic patients during the course of their treatment. Three developed proven invasive mucormycosis (IM), 17 had infections of known origin but other than IM, and 8 never had fever during the period of observation. Mucorales-specific T cells could be detected only in patients with IM, both at diagnosis and throughout the entire course of the IM, but neither before nor for long after resolution of the infection. Such T cells predominantly produced IL-4, IFN-gamma, IL-10, and to a lesser extent IL-17 and belonged to either CD4(+) or CD8(+) subsets. The specific T cells that produced IFN-gamma were able to directly induce damage to Mucorales hyphae. None of the 25 patients without IM had Mucorales-specific T cells. Specific T cells contribute to human immune responses against fungi of the order Mucorales and could be evaluated as a surrogate diagnostic marker of IM. (Blood. 2011;118(20):5416-5419)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Hematology

Feasibility of autologous peripheral blood stem cell mobilization and harvest in adult patients with FLT3-mutated acute myeloid leukemia receiving chemotherapy combined with midostaurin: a single-center experience

Stefano Cordella, Angelica Parisotto, Francesca Bettelli, Monica Morselli, Emiliano Barbieri, Stefano Pozzi, Anna Aquilino, Gianluca Repaci, Angela Cuoghi, Paola Bresciani, Andrea Messerotti, Corrado Colasante, Andrea Gilioli, Valeria Pioli, Davide Giusti, Elisabetta Colaci, Luca Cassanelli, Giovanni Ceccherelli, Mirco Bevini, Roberta Malavolti, Donatella Venturelli, Ambra Paolini, Silvia Martinelli, Rossana Maffei, Giovanni Riva, Vincenzo Nasillo, Tommaso Trenti, Patrizia Comoli, Enrico Tagliafico, Rossella Manfredini, Patrizia Barozzi, Leonardo Potenza, Roberto Marasca, Mario Luppi, Fabio Forghieri

ANNALS OF HEMATOLOGY (2023)

Article Hematology

SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia

Enrico Tiacci, Alessandro Mancini, Monia Marchetti, Gianna Maria D'Elia, Anna Candoni, Alessandro Morotti, Alessandra Romano, Alessandro Gozzetti, Alessandro Broccoli, Luca De Carolis, Riccardo Bruna, Maria Chiara Tisi, Carmine Selleri, Monia Capponi, Daniele Vallisa, Chiara Cattaneo, Matteo Giovanni Della Porta, Alessandro Busca, Brunangelo Falini, Massimo Massaia, Lorenza Bertu, Alessandro Pulsoni, Paolo Rivela, Paolo Corradini, Francesco Passamonti

Summary: Little is known about the course of COVID-19 and the antibody response to infection or vaccination in patients with hairy-cell leukaemia (HCL). In this study of 58 HCL cases, 37 unvaccinated patients developed COVID-19 with a generally favorable outcome, while active leukemia, older age, and comorbidities were associated with a worse course. Seroconversion consistently developed after infection (11 cases) and vaccination (28 cases), except in patients recently treated with anti-CD20 or venetoclax therapy. Vaccination appeared to protect against severe COVID-19 in patients with breakthrough infection.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Hematology

Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study

Michelina Dargenio, Massimiliano Bonifacio, Sabina Chiaretti, Antonella Vitale, Nicola Stefano Fracchiolla, Cristina Papayannidis, Fabio Giglio, Prassede Salutari, Ernesta Audisio, Barbara Scappini, Patrizia Zappasodi, Marzia Defina, Fabio Forghieri, Anna Maria Scattolin, Elisabetta Todisco, Monia Lunghi, Fabio Guolo, Maria Ilaria Del Principe, Mario Annunziata, Davide Lazzarotto, Michele Cedrone, Crescenza Pasciolla, Annalisa Imovilli, Ilaria Tanasi, Silvia Trappolini, Marco Cerrano, Roberta La Starza, Mauro Krampera, Nicola Di Renzo, Anna Candoni, Giovanni Pizzolo, Felicetto Ferrara, Robin Foa

Summary: This study analyzed the incidence, characteristics, treatment, and outcome of central nervous system (CNS) relapse in adult acute lymphoblastic leukemia (ALL) patients. The study found that 6.8% of patients experienced a CNS recurrence, with a higher incidence in T-cell ALL than in B-cell ALL. Risk factors for early CNS relapse included T-cell phenotype, hyperleucocytosis, and male gender. Treatment options varied, including chemotherapy, radiotherapy, intrathecal therapy, and novel agents. Allogenic transplant after complete remission showed a significant overall survival benefit. The time to CNS relapse was the strongest predictor of post-relapse survival.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Oncology

Prognostic Relevance of Multi-Antigenic Myeloma-Specific T-Cell Assay in Patients with Monoclonal Gammopathies

Ivana Lagreca, Vincenzo Nasillo, Patrizia Barozzi, Ilaria Castelli, Sabrina Basso, Sara Castellano, Ambra Paolini, Monica Maccaferri, Elisabetta Colaci, Daniela Vallerini, Patrizia Natali, Daria Debbia, Tommaso Pirotti, Anna Maria Ottomano, Rossana Maffei, Francesca Bettelli, Davide Giusti, Andrea Messerotti, Andrea Gilioli, Valeria Pioli, Giovanna Leonardi, Fabio Forghieri, Paola Bresciani, Angela Cuoghi, Monica Morselli, Rossella Manfredini, Giuseppe Longo, Anna Candoni, Roberto Marasca, Leonardo Potenza, Enrico Tagliafico, Tommaso Trenti, Patrizia Comoli, Mario Luppi, Giovanni Riva

Summary: This study sheds light on the dynamics of MM-specific T cells in patients with MGUS/SMM and introduces a new prognostic tool called MaMs T-cell assay, which may serve as an immunologic marker for effective disease control. The findings suggest that this assay can be routinely applied for risk assessment and prognostic evaluation in patients with monoclonal gammopathies.

CANCERS (2023)

Review Oncology

Role of Notch2 pathway in mature B cell malignancies

Nicolo Mesini, Stefania Fiorcari, Claudio Giacinto Atene, Rossana Maffei, Leonardo Potenza, Mario Luppi, Roberto Marasca

Summary: In recent decades, the Notch pathway has been recognized as an important regulatory signaling in cell-fate decisions and its alteration has been linked to tumor genesis and progression. The focus of this review is on the activity of Notch2 receptor, which has been found to be mutated in CLL, SMZL, and NMZL. A better understanding of the pathogenic role of Notch2 and the development of targeted therapies are desired.

FRONTIERS IN ONCOLOGY (2023)

Article Oncology

Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy

L. Maurillo, A. Spagnoli, A. Candoni, C. Papayannidis, E. Borlenghi, D. Lazzarotto, L. Fianchi, M. Sciume, M. E. Zannier, F. Buccisano, M. I. Del Principe, V. Mancini, M. Breccia, R. Fanin, E. Todisco, M. Lunghi, R. Palmieri, N. Fracchiolla, P. Musto, G. Rossi, A. Venditti

Summary: This study compared the efficacy of azacitidine and decitabine in elderly patients with untreated AML. The results showed similar outcomes in terms of complete remission, overall survival, and disease free survival between the two groups.

LEUKEMIA RESEARCH (2023)

Article Oncology

The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study

Giovanni Marconi, Anna Candoni, Roberta Di Nicola, Chiara Sartor, Sarah Parisi, Mariachiara Abbenante, Jacopo Nanni, Gianluca Cristiano, Letizia Zannoni, Davide Lazzarotto, Benedetta Giannini, Carmen Baldazzi, Lorenza Bandini, Emanuela Ottaviani, Nicoletta Testoni, Chiara Di Giovanni Bezzi, Rania Abd-alatif, Giulia Ciotti, Renato Fanin, Giovanni Martinelli, Stefania Paolini, Paolo Ricci, Michele Cavo, Cristina Papayannidis, Antonio Curti

Summary: In elderly AML patients, early response and biology-based risk classification can predict survival, but a comprehensive disease model has limitations in stratification. Baseline comorbidity burden may also impact prognosis. Therefore, a comprehensive approach that combines AML biology with tailored interventions to patients' frailty is likely to fully exploit the anti-leukemia potential of novel drugs.

CANCER MEDICINE (2023)

Article Oncology

Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)

Esther Natalie Oliva, Anna Candoni, Prassede Salutari, Giuseppe A. Palumbo, Gianluigi Reda, Giuseppe Ianni, Giovanni Tripepi, Maria Cuzzola, Debora Capelli, Corrado Mammi, Caterina Alati, Maria Concetta Cannata, Pasquale Niscola, Bianca Serio, Pellegrino Musto, Ernesto Vigna, Antonio Volpe, Lorella Maria Antonia Melillo, Maria Teresa Arcadi, Donato Mannina, Maria Elena Zannier, Roberto Latagliata

Summary: Azacitidine (AZA) is a hypomethylating agent used for frontline treatment of acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy. Recent research showed that maintenance therapy with AZA during complete remission improved disease-free survival (DFS) up to 2 and 5 years in AML patients aged >68 years.

CANCERS (2023)

Article Oncology

Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1mut) for the Treatment of NPM1mut-Acute Myeloid Leukemia

Marica De Cicco, Ivana Lagreca, Sabrina Basso, Patrizia Barozzi, Stella Muscianisi, Alba Bianco, Giovanni Riva, Sara Di Vincenzo, Chiara Pulvirenti, Davide Sapuppo, Mariangela Siciliano, Vittorio Rosti, Anna Candoni, Marco Zecca, Fabio Forghieri, Mario Luppi, Patrizia Comoli

Summary: This study investigated the feasibility of producing mutated-NPM1-specific cytotoxic T cells (CTLs) for the treatment of NPM1-mutated AML patients. The results showed that mutated-NPM1-specific CTLs with specific cytokine production and high cytotoxicity against patients' leukemia cells could be obtained from both patients and donors. These polyfunctional mutated-NPM1-specific CTLs included both CD8+ and CD4+ T cells with strong lytic capacity.

CANCERS (2023)

Letter Hematology

Pulmonary Actinomycosis by Actinomyces graevenitzii in Two Hematologic Patients

Gabriele Facchin, Giulia Battaglia, Assunta Sartor, Carla Fili, Maria Elena Zannier, Marta Lisa Battista, Renato Fanin, Anna Candoni

MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2023)

Article Oncology

Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in Real-Life: The SEIFEM Experience

Luana Fianchi, Fabio Guolo, Francesco Marchesi, Chiara Cattaneo, Michele Gottardi, Francesco Restuccia, Anna Candoni, Elettra Ortu La Barbera, Rita Fazzi, Crescenza Pasciolla, Olimpia Finizio, Nicola Fracchiolla, Mario Delia, Federica Lessi, Michelina Dargenio, Valentina Bonuomo, Maria Ilaria Del Principe, Patrizia Zappasodi, Marco Picardi, Claudia Basilico, Monica Piedimonte, Paola Minetto, Antonio Giordano, Patrizia Chiusolo, Lucia Prezioso, Caterina Buquicchio, Lorella Maria Antonia Melillo, Daniele Zama, Francesca Farina, Valentina Mancini, Irene Terrenato, Michela Rondoni, Irene Urbino, Mario Tumbarello, Alessandro Busca, Livio Pagano

Summary: This study evaluated the absolute infectious risk in 200 AML patients treated with CPX-351 and found it to have a good safety profile, with an incidence of infectious complications comparable to that of pivotal studies. The only factor significantly associated with mortality was a lack of response to CPX-351 treatment.

CANCERS (2023)

Correction Hematology

Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study (vol 199, pg 54, 2022)

V Marasco, A. Piciocchi, A. Candoni, L. Pagano, A. Guidetti, P. Musto

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Review Medicine, Research & Experimental

The dynamic functions of IRF4 in B cell malignancies

Rossana Maffei, Stefania Fiorcari, Claudio Giacinto Atene, Silvia Martinelli, Nicolo Mesini, Flora Pilato, Ivana Lagreca, Patrizia Barozzi, Giovanni Riva, Vincenzo Nasillo, Ambra Paolini, Fabio Forghieri, Leonardo Potenza, Tommaso Trenti, Enrico Tagliafico, Mario Luppi, Roberto Marasca

Summary: Interferon regulatory factor 4 (IRF4) plays a crucial role in regulating B cell development and is associated with B cell malignancies. The complexity of IRF4 functions includes its involvement in different DNA-binding affinity, target motifs, and transcriptional partners.

CLINICAL AND EXPERIMENTAL MEDICINE (2023)

暂无数据